IC Regimen: Delaying Resistance to Lorlatinib in ALK Driven Cancers Using Repurposed Itraconazole and Cilostazol
RE KAST - 2024 - preprints.org
This paper presents data supporting the IC Regimen for potentiating the effectiveness of
lorlatinib in treating ALK positive cancers, and specifically non-small cell lung cancer …
lorlatinib in treating ALK positive cancers, and specifically non-small cell lung cancer …